4-[(Dipropylamino)sulfanyl]benzoic acid | 919114-00-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(Dipropylamino)sulfanyl]benzoic acid
• 英文别名: 4-(dipropylamino)sulfanylbenzoic acid
• CAS: 919114-00-4
• 化学式: C₁₃H₁₉NO₂S
• 分子量: 253.36
• InChiKey: XPFFJFNNGAJPAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  65.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• PROBENECID FOR TREATING CORONAVIRUS INFECTIONS
  申请人：University of Georgia Research Foundation, Inc.

  公开号：EP3892269A1

  公开（公告）日：2021-10-13

  Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.

  提供了治疗冠状病毒感染受试者的组合物和方法。这些方法通常包括向受试者施用有效量的丙磺舒、其代谢物或类似物或其药学上可接受的盐。这些方法可用于治疗和/或预防。丙磺舒或其药学上可接受的盐的用量可以有效地减少病毒复制，减少与病毒有关的一种或多种疾病、紊乱或病症的症状，或其组合。在优选的实施方案中，病毒是严重急性呼吸系统综合征相关冠状病毒，如SARS-CoV-2或SARS-CoV，中东呼吸系统综合征相关冠状病毒，如MERS-CoV，或引起普通感冒的冠状病毒。
• THERAPEUTIC QUINAZOLINE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1218355A1

  公开（公告）日：2002-07-03
• A PROCESS FOR THE SYNTHESIS OF CARBON LABELED ORGANIC COMPOUNDS
  申请人：COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

  公开号：US20210107859A1

  公开（公告）日：2021-04-15

  A process for the synthesis of a carbon labeled organic compound containing a carbon labeled carboxyl group is described. A method of using carbon labeled organic compounds containing a carbon labeled carboxyl group according to the present disclosure; a process for manufacturing labeled pharmaceuticals and agrochemicals comprising synthesis of carbon labeled organic compounds containing a carbon labeled carboxyl group according to the present disclosure; and a process for producing tracers comprising synthesis of carbon labeled organic compounds containing a carbon labeled carboxyl group according to the present disclosure are also described.
• US7235559B1
  申请人：——

  公开号：US7235559B1

  公开（公告）日：2007-06-26
• [EN] THERAPEUTIC QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES THERAPEUTIQUES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2001021597A1

  公开（公告）日：2001-03-29

  A compound of formula (I) or a salt, ester, amide or prodrug thereof; where X is O, or S, S(O), S(O)2 or NR6 where R6 is hydrogen of C¿1-6?alkyl; R?5¿ is an optionally substituted 6-membered aromatic ring containing at least one nitrogen atom, and R?1, R2, R3, R4¿ are independently selected from halogeno, cyano, nitro, C¿1-3?alkylsulphanyl, -N(OH)R?7¿-(wherein R7 is hydrogen, or C¿1-3?alkyl), or R?9X1¿-(wherein X1represents a direct bond, -O-, -CH¿2?-, -OC(O), -C(O)-, -S-, -SO-, -SO2-, -NR?10¿C(O)-, -C(O)NR11-, -SO¿2?NR?12-, -NR13SO¿2- or NR14-(wherein R?10, R11, R12, R13 and R14¿ each independently represents hydrogen, C¿1-3?alkyl or C1-3alkoxyC2-3alkyl), and R?9¿ is hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy; provided that at least one of R2 or R3 is other than hydrogen. These compounds inhibit aurora 2 kinase and are useful in the preparation of medicaments for the treatment of proliferative disease such as cancer.